DAPT after PCI improves morbidity and mortality by reducing ischemic events but increases bleeding risk, especially for high bleeding risk patients. Nearly one-third of patients treated with PCI are considered to be at high bleeding risk, but these patients are frequently excluded from stent trials.

In a recent Cardiology article, Mohsin Chowdhury, MD, provides a brief primer on the use of antiplatelet therapy in high bleeding risk patients undergoing PCI in light of emerging data in this area. Read more.

Follow Cardiology on Twitter using #CardiologyMag and get the full issue here.